GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster
February 06, 2024 09:00 ET
|
GeoVax, Inc.
Results Demonstrate Potential Protective Immunity Against Multiple SARS-CoV-2 Variants ATLANTA, GA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a...
GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement
January 29, 2024 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology
January 08, 2024 09:00 ET
|
GeoVax, Inc.
Strengthening GeoVax’s Team Advancing Gedeptin® Clinical Program ATLANTA, GA, Jan. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...
GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients
January 04, 2024 09:00 ET
|
GeoVax, Inc.
Therapy Demonstrated Safety, Stabilization/Shrinkage of Treated Tumors Expanded Development for Monotherapy and Combination Therapy Anticipated ATLANTA, GA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- via...
GeoVax Announces Issuance of Malaria Vaccine Patent
January 03, 2024 09:00 ET
|
GeoVax, Inc.
Patent Covers Multiple Component Vaccine for Both Prevention and Treatment ATLANTA, GA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024
December 27, 2023 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, Dec. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox
December 19, 2023 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress
November 30, 2023 16:30 ET
|
GeoVax, Inc.
80% Survival in Nonhuman Primates Observed in a Lethal Challenge Model ATLANTA, GA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...
GeoVax to Participate in Upcoming December Investor Events
November 29, 2023 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, Nov. 29, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress
November 28, 2023 09:00 ET
|
GeoVax, Inc.
Presentation of Data from Phase 2 Open-Label Study of GEO-CM04S1 Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients ATLANTA,...